Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lexaria Bioscience (LEXX) EPS (Weighted Average and Diluted) (2023 - 2025)

Lexaria Bioscience's EPS (Weighted Average and Diluted) history spans 3 years, with the latest figure at -$0.07 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 56.25% year-over-year to -$0.07; the TTM value through Nov 2025 reached -$0.57, down 14.0%, while the annual FY2025 figure was -$0.66, 40.43% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.07 at Lexaria Bioscience, up from -$0.13 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.18 in Q3 2023 and bottomed at -$0.21 in Q2 2025.
  • The 3-year median for EPS (Weighted Average and Diluted) is -$0.13 (2023), against an average of -$0.1.
  • The largest annual shift saw EPS (Weighted Average and Diluted) tumbled 182.68% in 2024 before it surged 56.25% in 2025.
  • A 3-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.13 in 2023, then fell by 23.08% to -$0.16 in 2024, then soared by 56.25% to -$0.07 in 2025.
  • Per Business Quant, the three most recent readings for LEXX's EPS (Weighted Average and Diluted) are -$0.07 (Q4 2025), -$0.13 (Q3 2025), and -$0.21 (Q2 2025).